The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol

Laurien J. Zeverijn; Birgit S. Geurts; Thomas Battaglia; Jade M. van Berge Henegouwen; Gijs F. de Wit; Louisa R. Hoes; Hanneke van der Wijngaart; Vincent van der Noort; Paul Roepman; Wendy W.J. de Leng; Anne M.L. Jansen; Myriam Chalabi; Carla M.L. van Herpen; Lot A. Devriese; Frans Erdkamp; Mariëtte Labots; Maja J.A. de Jonge; Emile D. Kerver; Adriaan D. Bins; Lindsay V.M. Leek; Jessica C.L. Notohardjo; Alfons J.M. van den Eertwegh; Lodewyk F.A. Wessels; Henk M.W. Verheul; Hans Gelderblom; Joris van de Haar; Emile E. Voest

doi:10.1158/1078-0432.ccr-24-0480

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zeverijn et al. (2024) studied this question.

synapsesocial.com/papers/68e5fdb9b6db6435875918c6 https://doi.org/10.1158/1078-0432.ccr-24-0480

View at Publisher

Ask AI

Bookmark

Share

The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol

Ask about this paper

Abstract

Discussion

Cite This Study

The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading